Skip to main content
Erschienen in: Familial Cancer 3/2011

01.09.2011

Malignant fibrous histiocytoma is a rare Lynch syndrome-associated tumor in two German families

verfasst von: Angela Brieger, Knut Engels, Dieter Schaefer, Guido Plotz, Stefan Zeuzem, Jochen Raedle, Joerg Trojan

Erschienen in: Familial Cancer | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Lynch syndrome is characterized by germline mutations of the DNA mismatch repair genes MLH1 and MSH2. The tumor spectrum includes early onset colorectal, urogenital and other cancers. Soft tissue sarcomas have been anecdotally reported in patients with Lynch syndrome, but coincidental manifestation could not be excluded. In this report, we screened a cohort of Lynch syndrome families for tumors outside the established tumor spectrum. We identified two patients with Lynch syndrome and a malignant fibrous histiocytoma (MFH). In both families a causative MSH2 germline mutation (MSH2 c.2038C ≥ T or MSH2 c.942 ± 3A ≥ T) could be detected. Archival tumor material from both resected MFH was analyzed for microsatellite instability expression of MLH1 and MSH2. A mutator phenotype was detected in both MFH with loss of MSH2 protein expression. Subsequently, the causative MSH2 germline mutation was confirmed in both patients. Of note, both tumors were diagnosed at a local advanced stage but could be curatively resected 21 and 11 year ago, respectively. Both patients are alive without local or distant recurrence. In conclusion, our data further support that patients with Lynch syndrome are at increased risk for rare tumors such as MFH. However, the prognosis compared to sporadic MFH seems to be favorable.
Literatur
1.
Zurück zum Zitat Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348(10):919–932 Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348(10):919–932
2.
Zurück zum Zitat Hampel H, Frankel WL, Martin E et al (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352(18):1851–1860 Hampel H, Frankel WL, Martin E et al (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352(18):1851–1860
3.
Zurück zum Zitat Vasen HF, Moslein G, Alonso A et al (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44(6):353–362PubMedCrossRef Vasen HF, Moslein G, Alonso A et al (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44(6):353–362PubMedCrossRef
4.
Zurück zum Zitat Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261–268 Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261–268
5.
Zurück zum Zitat Meyer C, Brieger A, Plotz G et al (2009) An interstitial deletion at 3p21.3 results in the genetic fusion of MLH1 and ITGA9 in a Lynch syndrome family. Clin Cancer Res 15(3):762–769 Meyer C, Brieger A, Plotz G et al (2009) An interstitial deletion at 3p21.3 results in the genetic fusion of MLH1 and ITGA9 in a Lynch syndrome family. Clin Cancer Res 15(3):762–769
6.
Zurück zum Zitat Walsh MD, Buchanan DD, Cummings MC et al (2010) Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. Clin Cancer Res 16(7):2214–2224. Walsh MD, Buchanan DD, Cummings MC et al (2010) Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. Clin Cancer Res 16(7):2214–2224.
7.
Zurück zum Zitat Bauer CM, Ray AM, Halstead-Nussloch BA et al (2011) Hereditary prostate cancer as a feature of Lynch syndrome. Fam Cancer 10(1):37–42 Bauer CM, Ray AM, Halstead-Nussloch BA et al (2011) Hereditary prostate cancer as a feature of Lynch syndrome. Fam Cancer 10(1):37–42
8.
Zurück zum Zitat Arana VM, del Pino YB, Garcia-Castro C, Gonzalez-Aguilera JJ, Fernandez-Peralta A, Hermoso FG (2002) Highly aggressive leiomyosarcoma associated with Lynch II syndrome: increasing the range of extracolonic cancers related with hereditary non-polyposis colonic cancer. Annals Oncol 13(5):807–808CrossRef Arana VM, del Pino YB, Garcia-Castro C, Gonzalez-Aguilera JJ, Fernandez-Peralta A, Hermoso FG (2002) Highly aggressive leiomyosarcoma associated with Lynch II syndrome: increasing the range of extracolonic cancers related with hereditary non-polyposis colonic cancer. Annals Oncol 13(5):807–808CrossRef
9.
Zurück zum Zitat den Bakker MA, Seynaeve C, Kliffen M, Dinjens WN (2003) Microsatellite instability in a pleomorphic rhabdomyosarcoma in a patient with hereditary non-polyposis colorectal cancer. Histopathology 43(3):297–299CrossRef den Bakker MA, Seynaeve C, Kliffen M, Dinjens WN (2003) Microsatellite instability in a pleomorphic rhabdomyosarcoma in a patient with hereditary non-polyposis colorectal cancer. Histopathology 43(3):297–299CrossRef
10.
Zurück zum Zitat Sijmons R, Hofstra R, Hollema H et al (2000) Inclusion of malignant fibrous histiocytoma in the tumour spectrum associated with hereditary non-polyposis colorectal cancer. Genes Chromosom Cancer 29(4):353–355PubMedCrossRef Sijmons R, Hofstra R, Hollema H et al (2000) Inclusion of malignant fibrous histiocytoma in the tumour spectrum associated with hereditary non-polyposis colorectal cancer. Genes Chromosom Cancer 29(4):353–355PubMedCrossRef
11.
Zurück zum Zitat Kratz CP, Holter S, Etzler J et al (2009) Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome. J Med Genet 46(6):418–420PubMedCrossRef Kratz CP, Holter S, Etzler J et al (2009) Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome. J Med Genet 46(6):418–420PubMedCrossRef
12.
Zurück zum Zitat Hirata K, Kanemitsu S, Nakayama Y et al (2006) A novel germline mutation of MSH2 in a hereditary nonpolyposis colorectal cancer patient with liposarcoma. J Gastroenterol 101(1):193–196 Hirata K, Kanemitsu S, Nakayama Y et al (2006) A novel germline mutation of MSH2 in a hereditary nonpolyposis colorectal cancer patient with liposarcoma. J Gastroenterol 101(1):193–196
13.
Zurück zum Zitat Nilbert M, Therkildsen C, Nissen A, Akerman M, Bernstein I (2009) Sarcomas associated with hereditary nonpolyposis colorectal cancer: broad anatomical, morphological spectrum. Familial Cancer 8(3):209–213PubMedCrossRef Nilbert M, Therkildsen C, Nissen A, Akerman M, Bernstein I (2009) Sarcomas associated with hereditary nonpolyposis colorectal cancer: broad anatomical, morphological spectrum. Familial Cancer 8(3):209–213PubMedCrossRef
14.
Zurück zum Zitat Pineda M, Gonzalez S, Lazaro C, Blanco I, Capella G (2010) Detection of genetic alterations in hereditary colorectal cancer screening. Mutat Res 693(1–2):19–31 Pineda M, Gonzalez S, Lazaro C, Blanco I, Capella G (2010) Detection of genetic alterations in hereditary colorectal cancer screening. Mutat Res 693(1–2):19–31
15.
Zurück zum Zitat Liu B, Parsons RE, Hamilton SR et al (1994) hMSH2 mutations in hereditary nonpolyposis colorectal cancer kindreds. Cancer Res 54(17):4590–4594 Liu B, Parsons RE, Hamilton SR et al (1994) hMSH2 mutations in hereditary nonpolyposis colorectal cancer kindreds. Cancer Res 54(17):4590–4594
16.
Zurück zum Zitat Kolodner RD, Hall NR, Lipford J et al (1995) Structure of the human MLH1 locus and analysis of a large hereditary nonpolyposis colorectal carcinoma kindred for mlh1 mutations. Cancer Res 55(2):242–248 Kolodner RD, Hall NR, Lipford J et al (1995) Structure of the human MLH1 locus and analysis of a large hereditary nonpolyposis colorectal carcinoma kindred for mlh1 mutations. Cancer Res 55(2):242–248
17.
Zurück zum Zitat Hampel H, Frankel W, Panescu J et al (2006) Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66(15):7810–7817 Hampel H, Frankel W, Panescu J et al (2006) Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66(15):7810–7817
18.
Zurück zum Zitat Martin SS, Hurt WG, Hedges LK, Butler MG, Schwartz HS (1998) Microsatellite instability in sarcomas. Ann Surg Oncol 5(4):356–360PubMedCrossRef Martin SS, Hurt WG, Hedges LK, Butler MG, Schwartz HS (1998) Microsatellite instability in sarcomas. Ann Surg Oncol 5(4):356–360PubMedCrossRef
19.
Zurück zum Zitat Vasen HF, Stormorken A, Menko FH et al (2001) MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 19(20):4074–4080 Vasen HF, Stormorken A, Menko FH et al (2001) MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 19(20):4074–4080
20.
Zurück zum Zitat Shinjo K (1994) Analysis of prognostic factors, chemotherapy of malignant fibrous histiocytoma of soft tissue: a preliminary report. Jpn J Clin Oncol 24(3):154–159PubMed Shinjo K (1994) Analysis of prognostic factors, chemotherapy of malignant fibrous histiocytoma of soft tissue: a preliminary report. Jpn J Clin Oncol 24(3):154–159PubMed
21.
Zurück zum Zitat Weiss SW, Enzinger FM (1978) Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer 41(6):2250–2266PubMedCrossRef Weiss SW, Enzinger FM (1978) Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer 41(6):2250–2266PubMedCrossRef
22.
Zurück zum Zitat Matushansky I, Charytonowicz E, Mills J, Siddiqi S, Hricik T, Cordon-Cardo C (2009) MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century. Expert Rev Anticancer Ther 9(8):1135–1144PubMedCrossRef Matushansky I, Charytonowicz E, Mills J, Siddiqi S, Hricik T, Cordon-Cardo C (2009) MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century. Expert Rev Anticancer Ther 9(8):1135–1144PubMedCrossRef
Metadaten
Titel
Malignant fibrous histiocytoma is a rare Lynch syndrome-associated tumor in two German families
verfasst von
Angela Brieger
Knut Engels
Dieter Schaefer
Guido Plotz
Stefan Zeuzem
Jochen Raedle
Joerg Trojan
Publikationsdatum
01.09.2011
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 3/2011
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-011-9455-9

Weitere Artikel der Ausgabe 3/2011

Familial Cancer 3/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.